• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 31, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Women can breathe sigh of relief when using vaginal estrogen to treat menopause symptoms

Bioengineer by Bioengineer
October 11, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CLEVELAND, Ohio (Oct. 11, 2017) — News flash….hot flashes aren't the only bothersome symptom of the menopause transition. Many postmenopausal women also experience sexual dysfunction and urinary problems that don't require estrogen pills but, rather, can be alleviated by vaginally administered estrogen. A new study shows that, despite previous misperceptions, this treatment option is not only effective, but also safe. The study results will be presented during The North American Menopause Society (NAMS) Annual Meeting in Philadelphia, October 11-14.

Vaginal estrogen in the form of a cream or suppository is highly effective in managing an array of sexual and urinary problems collectively referred to as the genitourinary syndrome of menopause. Despite its proven effectiveness, the use of vaginal estrogen has been restricted by concerns of women and their healthcare providers regarding its potential link to such serious health issues as coronary heart disease, breast cancer, stroke, and others. Examination of the data from the Women's Health Initiative (WHI) Observational Study of more than 45,000 participants showed, however, that the use of vaginal estrogen does not significantly increase the risk of heart disease or cancer, including breast, colorectal, and endometrial cancer. Nor is it related to an elevated risk of such other concerns as stroke, pulmonary embolism, hip fracture, or death.

"These results should help reassure women regarding the safety of vaginal estrogen," says Dr. Carolyn Crandall, lead author of the study from the University of California in Los Angeles.

"Studies like these are so valuable to help dispel misperceptions that keep women from getting the relief they seek," says Dr. JoAnn Pinkerton, NAMS executive director. "Women and their healthcare providers need to be armed with the latest facts so they can make informed decisions regarding their treatment options."

Drs. Crandall and Pinkerton are available for interviews before the presentation at the Annual Meeting.

###

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field–including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education–makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit http://www.menopause.org.

Media Contact

Eileen Petridis
[email protected]
216-696-0229
@MenopauseOrg

http://www.menopause.org

http://www.menopause.org/docs/default-source/default-document-library/vaginal-estrogen-cancer-and-heart-disease-10-3-17.pdf

Share14Tweet8Share2ShareShareShare2

Related Posts

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

August 31, 2026
Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

August 31, 2026

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

August 31, 2026

Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

August 31, 2026
Please login to join discussion

POPULAR NEWS

  • β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

    29 shares
    Share 12 Tweet 7
  • Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

    29 shares
    Share 12 Tweet 7
  • KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

    29 shares
    Share 12 Tweet 7
  • Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.